You Can’t Patent LSD
Motley Fool Money
00:00
Psychedelic Stocks: A Market Reality Check
This chapter examines the shifting landscape of psychedelic drug companies, focusing on the decline in stock valuations and regulatory hurdles faced by key players like Compass Pathways. It discusses the complexities of clinical trials, including issues with double-blind studies due to the nature of psychedelics, and explores the differences between the psychedelic and cannabis markets. Additionally, the chapter highlights innovative strategies within the industry and the financial risks associated with investing in this emerging sector.
Transcript
Play full episode
